Phase 1 NSCLC Combination Trial Terminated Early Due to Toxicity

Drug Profile

The terminated trial evaluated a combination of two distinct targeted agents.

Capmatinib is a highly selective, ATP-competitive, reversible inhibitor of the MET receptor tyrosine kinase. It is approved as a monotherapy (Tabrecta) for adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping. By binding to the MET kinase domain, capmatinib blocks signaling through pathways like RAS/RAF/MEK/ERK and PI3K/AKT, which are critical for tumor cell proliferation, survival, and migration.

Trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and 2 (MEK2) activation and kinase activity. It is approved (Mekinist) for use in combination with a BRAF inhibitor for certain melanomas, NSCLC, and other cancers with BRAF V600 mutations. Trametinib targets a key downstream component of the RAS/RAF pathway. The rationale for combining it with capmatinib was to create a vertical blockade of the same signaling cascade at two different points, a strategy intended to overcome or prevent acquired resistance to MET inhibition alone.

Clinical Data

The trial was a single-arm, dose-escalation study designed to find the maximum tolerated dose (MTD) and recommended Phase 2 dose. Data is limited to the first dose-level cohort of three patients before termination (https://www.medrxiv.org/content/10.64898/2026.05.19.26353265v1).

| Endpoint | Result | Comparator | Trial Name/ID | | :--- | :--- | :--- | :--- | | Safety / Tolerability | MTD not established. All 3 patients experienced dose-limiting toxicities leading to treatment discontinuation. | N/A (Single Arm) | Phase 1 Investigator-Initiated Trial | | Objective Response Rate (ORR)| 0% (0 of 3 patients) | N/A (Single Arm) | Phase 1 Investigator-Initiated Trial |

Global Regulatory Status

Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.

STATUS

This was an early-stage academic trial; no regulatory submissions for the combination therapy have been filed.

Market Impact

The failure of the capmatinib/trametinib combination is a setback for developing therapies for MET-driven NSCLC patients after they acquire resistance to first-line MET inhibitors. Approved monotherapies like capmatinib and tepotinib have established a clear standard of care, but resistance mechanisms, often involving reactivation of the MAPK pathway, inevitably emerge. This trial attempted to address that specific mechanism directly. Its termination due to toxicity suggests that the therapeutic window for a MET+MEK inhibitor combination is likely nonexistent or extremely narrow in this population. Competitors developing other combination strategies, such as those pairing MET inhibitors with EGFR inhibitors, checkpoint inhibitors, or novel agents, may now see a clearer, albeit still challenging, path forward. This result will likely suppress further investment in MET+MEK combinations for NSCLC.

This outcome reinforces a critical structural force in oncology drug development: the high tolerability barrier for combination therapies. As monotherapies become more potent and targeted, any add-on agent must provide a substantial efficacy benefit to justify the cumulative toxicity. The theoretical synergy of blocking two nodes in a single pathway did not translate into a clinically viable regimen, demonstrating that preclinical rationale is insufficient for predicting human tolerance. This failure emphasizes the industry's need for more sophisticated preclinical models that can better predict on-target, off-tumor toxicities. It also pushes the field toward developing more refined approaches, such as antibody-drug conjugates or molecular glues, that might achieve potent pathway inhibition with a more manageable safety profile than dual small-molecule kinase inhibitors.